The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Five reasons why Astra should buy Gilead, and five why a move of this sort is pure fantasy.
Drug makers struck few M&A deals in the first quarter, but activity did not dry up, suggesting that the real impact of coronavirus has yet to play out.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
Two acquisitions of cell therapy companies could take them in almost opposite directions.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
The cell therapy player, aiming to take TILs out of academia into a commercial setting, has surged on unsubstantiated takeover rumours.